Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 11:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drugs, Investigational Clear all
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

NCT05050136
View directory record Official record
Conditions
Primary Biliary Cholangitis, PBC
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis

NCT03486912
View directory record Official record
Conditions
Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis
Interventions
BMS-986036, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
85
States / cities
Madison, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Jun 10, 2026, 11:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

NCT04663308
View directory record Official record
Conditions
Primary Sclerosing Cholangitis
Interventions
Volixibat, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
34
States / cities
Coronado, California • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Jun 10, 2026, 11:14 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Fort Lauderdale, Florida • Reno, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 10, 2026, 11:14 PM EDT
Completed No phase listed Observational

Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials

NCT00949390
View directory record Official record
Conditions
Advanced Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

A Chemoprevention Study of an Investigational Drug in Men With High Grade Prostate Intraepithelial Neoplasia (PIN)

NCT00028353
View directory record Official record
Conditions
Prostatic Intraepithelial Neoplasia
Interventions
GTX-006 (Acapodene)
Drug
Lead sponsor
GTx
Industry
Eligibility
30 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Aventura, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Jun 10, 2026, 11:14 PM EDT
Withdrawn Phase 2 Interventional

Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine

NCT02246075
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Cognition
Interventions
EVP-6124
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
2
States / cities
Delray Beach, Florida • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 1 Interventional Results available

Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer

NCT00965731
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Erlotinib, PF-02341066
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Fort Lauderdale, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

Carbidopa for the Treatment of Excessive Blood Pressure Variability

NCT02553265
View directory record Official record
Conditions
Dysautonomia, Familial, Baroreflex Failure Syndrome
Interventions
Carbidopa Low-Dose, Placebo, Carbidopa High-Dose
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
10 Years to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Jun 10, 2026, 11:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rabies Immune Plasma Booster Study

NCT01063140
View directory record Official record
Conditions
Rabies
Interventions
Rabies Vaccine (RabAvert), Rabies Vaccine (Imovax)
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Tempe, Arizona • Rock Island, Illinois • Oak Park, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2015 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 2 Interventional

XEN1101 for Major Depressive Disorder

NCT04827901
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
XEN1101, Placebo
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

NCT01101334
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer (NSCLC)
Interventions
CS-7017, erlotinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Denver, Colorado • Canton, Ohio • Everett, Washington
Source: ClinicalTrials.gov public record
Updated Jun 15, 2020 · Synced Jun 10, 2026, 11:14 PM EDT
Terminated Phase 2Phase 3 Interventional

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

NCT05490563
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 3
Interventions
SLS-005, Placebo
Drug
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of L-697,661 Alone and in Combination With Zidovudine

NCT00000628
View directory record Official record
Conditions
HIV Infections
Interventions
L-697,661, Zidovudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2008 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

NCT00603746
View directory record Official record
Conditions
Asthma
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
94
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Not applicable Interventional

A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children

NCT00000634
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 13 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Jun 10, 2026, 11:14 PM EDT
Terminated Phase 3 Interventional

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

NCT00006187
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Investigational drug
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
34
States / cities
Peoria, Arizona • Beverly Hills, California • Los Alamitos, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 1 Interventional

Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

NCT01284192
View directory record Official record
Conditions
Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS, Solid Tumor, B-Cell Lymphoma
Interventions
ASP3026
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
Orange, California • Sacramento, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Jun 10, 2026, 11:14 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge

NCT02639299
View directory record Official record
Conditions
Malaria
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 11:14 PM EDT
Available No phase listed Expanded access

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

NCT06980519
View directory record Official record
Conditions
Cancer, Solid Tumor, Solid Tumor Cancer, Oncology, uPAR-positive Solid Tumor, Urokinase Plasminogen Activator Receptor-positive Solid Tumor
Interventions
MNPR-101-PCTA-177Lu
Biological
Lead sponsor
Monopar Therapeutics
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 1 Interventional

Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma

NCT00036140
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Investigational drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • Rancho Mirage, California • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 11:14 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo comparator
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Jun 10, 2026, 11:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT07186842
View directory record Official record
Conditions
Advanced Solid Cancers
Interventions
BNT329, CA19-9-targeting monoclonal antibody
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 10, 2026, 11:14 PM EDT